AC
TOVX icon

Armistice Capital’s Theriva Biologics TOVX Stock Holding History

Armistice Capital’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$138K – 299
2024
Q3 		$138K Buy
+100,000
New +$488K ﹤0.01% 228
2019
Q1 		– Sell
-2,228
Closed -$312K – 87
2018
Q4 		$312K Buy
+2,228
New +$529K 0.02% 66

Other funds holding TOVX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
IHWM
Iron Horse Wealth Management Johston, Iowa $339M AUM 10.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Armistice Capital's TOVX Position: Q4 2024 in Review

Armistice Capital sold out of Theriva Biologics (TOVX) in Q4 2024, closing a stake of 100,000 shares — an estimated $138K sold.

Armistice Capital first reported a position in TOVX in Q4 2018 and held it in 2 quarters. The position peaked at $312K in Q4 2018. 10 funds tracked by Wall St. Rank hold TOVX as of Q4 2024.

  • Armistice Capital reported no remaining Theriva Biologics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 100,000 Theriva Biologics shares in Q4 2024, an estimated $138K.
  • Armistice Capital first reported a position in Theriva Biologics in Q4 2018 and held it in 2 quarters.
  • Armistice Capital's Theriva Biologics position peaked at $312K in Q4 2018.
  • 10 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.